Nutritional compositions, products comprising same and uses thereof

Abstract

Disclosed are nutritional compositions, products comprising the same, and their uses. The nutritional compositions comprise 2'-fucosylated lactose and 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride. The nutritional compositions are used to prepare products for improving vision (e.g., protecting against blue light damage and / or preventing myopia).

Description

Technical Field

[0001] This invention relates to the field of food, and particularly to the field of functional nutrients. Specifically, this invention relates to nutritional compositions, products comprising the same, and their use in the preparation of products, such as foods, for improving vision, for example, protecting against blue light damage and / or preventing myopia. Background Technology

[0002] Smartphones, computers, and other electronic display devices are increasingly used in daily life. Many electronic screens emit blue light. If the eyes are exposed to harmful blue light for a long time, it may cause diseases such as myopia, dry eye, cataracts, and keratitis. High-energy blue light will produce excessive reactive oxygen species (ROS) in the eyes, affecting the structure and function of mitochondria, triggering their participation in death signaling pathways, inducing apoptosis, and thus causing eye damage and vision loss (Liu Jiachen, Liu Fei, Wang Zefei, Research progress on the mechanism of action and prevention of blue light damage to the eyes, Chinese Journal of Eyewear Technology, 2025, (08):96-99).

[0003] Furthermore, myopia is becoming increasingly common among teenagers worldwide. Once myopia develops, it can range from impacting daily life to severely affecting the physical and mental health development of teenagers.

[0004] Therefore, it is desirable to develop methods that can effectively protect and improve vision, such as protecting against blue light damage and / or preventing myopia.

[0005] 2'-Fucosyllactose (also known as 2'-FL) is one of the main oligosaccharides found in breast milk. It can now be produced using environmentally friendly and efficient biosynthetic technologies and was approved as a food fortifier in my country in 2023. Studies have shown that 2'-FL, as the most abundant oligosaccharide in breast milk, has multiple biological functions, including regulating intestinal flora balance, maintaining the intestinal barrier, enhancing immunity, and supporting neural development. CN118303620B discloses a composition for improving eye fatigue, which is composed of *Bifidobacterium longum* subsp. i772, 2'-FL, lactose-N-neotetrasaccharide, and lutein. This literature demonstrates that the composition can effectively alleviate ocular cell apoptosis caused by eye fatigue through a zebrafish eye fatigue model established by water-soluble administration of mycophenolate mofetil. However, this literature did not investigate whether 2'-FL has anti-blue light damage and myopia prevention effects through animal experiments such as blue light damage modeling and myopia modeling. CN118765978A discloses the efficacy of milk phospholipids and / or 2'-FL in improving ocular apoptosis in an ocular apoptosis model established by water-soluble administration of mycophenolate mofetil and in improving ocular histopathology in a macular degeneration model. However, this literature did not conduct experimental studies to investigate the efficacy of 2'-FL and compositions including it in protecting against blue light damage and preventing myopia.

[0006] UPU-type triglycerides refer to a class of triglycerides in which unsaturated fatty acids are linked to the sn-1 and sn-3 positions of the glycerol backbone, and palmitic acid is linked to the sn-2 position; specifically, 1,3-diunsaturated fatty acid-2-palmitoyl triglycerides. They can reduce the hardness of infant stools, promote the absorption of fats and minerals, and protect intestinal health. CN119999921B discloses a nutritional composition containing medium- and long-chain triglycerides (MLCT) and nervonic acid, which has the effect of relieving eye fatigue and improving vision. MLCTs are a class of structural lipids whose molecules simultaneously contain both medium-chain and long-chain fatty acids, exhibiting different physicochemical properties, metabolic characteristics, and nutritional value compared to long-chain or medium-chain triglycerides. However, MLCT is not equivalent to UPU, and MLCT in breast milk is mostly SSU type (S represents saturated fatty acid, U represents unsaturated fatty acid) (Wang Lei, Compositional Characteristics of Breast Milk Triglycerides and Digestive Properties of Breast Milk Structured Fat, Jiangnan University, 2022). That is, MLCT is mostly a case where one unsaturated fatty acid and two saturated fatty acids are linked to the glycerol backbone, while UPU belongs to SUU type, that is, the glycerol backbone of UPU is linked to two unsaturated fatty acids and one saturated fatty acid, and the saturated fatty acid is palmitic acid, linked at the sn-2 position. CN118436084B discloses a nutritional composition for alleviating blue light damage, which contains 1,3-dioleoyl-2-palmitoylglycerol (OPO) and taurine. However, this document does not disclose the combination of OPO with other components. In addition, there are currently no reports on the effects of structural lipids including multiple UPU-type triglycerides on anti-blue light damage and myopia prevention.

[0007] Therefore, there is still a need to develop products and methods that can effectively protect and improve human vision, such as protecting against blue light damage and / or preventing myopia. Summary of the Invention

[0008] In a first aspect, the present invention provides a nutritional composition capable of effectively improving vision, such as protecting against blue light damage and / or preventing myopia. The nutritional composition comprises 2'-fucosylated lactose (2'-FL) and 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride (UPU).

[0009] In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol may be in the range of 0.01:1 to 20:1, preferably 0.05:1 to 15:1, more preferably 0.07:1 to 13:1, further preferably 0.08:1 to 4:1, even more preferably 0.22:1 to 3.2:1, and still more preferably 0.25:1 to 0.8:1.

[0010] The 1,3-diunsaturated fatty acid-2-palmitoyl triglyceride (UPU) may include one or more of the following: 1,3-dioleoyl-2-palmitoyl triglyceride (OPO), 1-oleic-2-palmitoyl-3-linoleic triglyceride (OPL), and 1,3-dilinoleic-2-palmitoyl triglyceride (LPL).

[0011] In some embodiments, in the UPU, based on a total triglyceride content of 100%, the OPL mass percentage is 12% to 40% (e.g., 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 22%, 25%, 30%, 35%, or 40%), and the OPO mass percentage is 5% to 35% (e.g., 5%, 6%, 7%, 8%, 9%, 10%, 15%, 16%, 17%, 18%, 19%, 20%, 22%, 25%, 30%, or 35%), L The PL mass percentage is 0.3% to 10% (e.g., 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 2.0%, 3.0%, 4.0%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, or 10.0%), and the sum of the masses of OPO, OPL, and LPL is ≥35% (e.g., ≥35%, ≥36%, ≥37%, ≥38%, ≥39%, ≥40%, ≥45%, ≥50%, or higher, more specifically, 50%). For example, in the UPU, with a total triglyceride content of 100%, the sum of the masses of OPO, OPL, and LPL can be in the range of 35% to 100%, e.g., 40% to 80%, 40% to 60%, or 40% to 50%.

[0012] In a second aspect, the present invention provides products comprising a nutritional composition according to the first aspect of the present invention.

[0013] The product may be food or medicine.

[0014] The product may further include one or more ingredients selected from plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives, and food ingredients.

[0015] The food products may include dairy products, health foods, fermented foods, beverages, bread, biscuits, and confectionery.

[0016] The food products may be infant formula, children's formula, youth formula, formula for pregnant women, or formula for the middle-aged and elderly.

[0017] In a third aspect, the present invention provides the use of a nutritional composition according to the first aspect of the present invention for preparing a product for improving vision.

[0018] The improvement in vision may include protection against blue light damage and / or prevention of myopia.

[0019] The inventors have discovered through research that consuming or taking the nutritional composition described above can effectively improve vision, such as by protecting against blue light damage and / or preventing myopia. In particular, when 2'-FL and UPU are used in combination, there is a synergistic effect between them, which can enhance the effect of improving vision, such as protecting against blue light damage and / or preventing myopia. Attached Figure Description

[0020] Figure 1 To evaluate the fluorescence intensity statistics of apoptotic cells in the zebrafish eyes during Experiment 1. Figure 1 In comparison with the model control group, *p < 0.05, **p < 0.01, ***p < 0.001; compared with Comparative Example 1, # p < 0.05; compared with Comparative Example 2, ^p < 0.05; compared with Comparative Example 3, $$ p < 0.01; compared with Comparative Example 4, %% p < 0.01, %%% p < 0.001; compared with Comparative Example 5, & p < 0.05. The statement "*p < 0.05 compared to the model control group" means that "* indicates p < 0.05 compared to the model control group"; the statement "*p < 0.05 compared to Comparative Example 1" means that p < 0.05 compared to Comparative Example 1. # "p < 0.05" means that # This indicates that compared with Comparative Example 1, p < 0.05; the same applies to the others.

[0021] Figure 2 To evaluate the fluorescence of apoptotic cells in the zebrafish eye in Experiment 1. The area within the yellow dashed box represents the eye analysis region, and the green fluorescent particles indicated by the red arrows represent apoptotic cells.

[0022] Figure 3 To evaluate the statistical graph of ROS fluorescence values ​​in the eyes of zebrafish in Experiment 1. Figure 3In comparison with the model control group, *p < 0.05, **p < 0.01, ***p < 0.001; compared with Comparative Example 1, # p < 0.05, ## p < 0.01; compared with Comparative Example 2, ^p < 0.05; compared with Comparative Example 4, % p < 0.05, %%% p < 0.001; compared with Comparative Example 5, & p < 0.05.

[0023] Figure 4 A statistical graph to evaluate the ratio of zebrafish retinal pigment epithelium diameter to scleral diameter in Experiment 2. Figure 4 In comparison with the model control group, *p < 0.05, **p < 0.01, ***p < 0.001; compared with Comparative Example 1, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with Comparative Example 2, p < 0.01; compared with Comparative Example 4, %%% p < 0.001; compared with Comparative Example 5, && p < 0.01.

[0024] Figure 5 Photographs showing the ratio of retinal pigment epithelium diameter to scleral diameter in zebrafish from Experiment 2. Red arrows indicate retinal pigment epithelium diameter, and yellow arrows indicate scleral diameter. Detailed Implementation

[0025] The following definitions are provided to enable those skilled in the art to understand the invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Preferred materials and methods are described herein, but any methods and materials similar to or equivalent to those described herein may be used in the practice of testing the invention. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0026] Terminology Definition

[0027] Unless otherwise specified or defined, all terms used have their ordinary meaning in the art as understood by those skilled in the art. Furthermore, unless otherwise stated, all methods, steps, techniques, and operations not specifically detailed herein can and have been performed in a manner known per se to those skilled in the art.

[0028] As used herein, the term "2'-fucosylated lactose" (or "2'-FL") refers to a human milk oligosaccharide with the molecular formula C2. 18 H 32 O 15 And its molecular weight is 488.439 g / mol.

[0029] As used herein, the term "1,3-diunsaturated fatty acid-2-palmitoylglycerol" (also known as "UPU") ​​refers to a class of triglycerides in which unsaturated fatty acids are attached to the sn-1 and sn-3 positions of the glycerol backbone and palmitic acid is attached to the sn-2 position. In other words, it refers to triglycerides represented in the form of "ABC" with A attached to the sn-1 position, B attached to the sn-2 position, and C attached to the sn-3 position, where A and C are unsaturated fatty acids and B is palmitic acid.

[0030] The present invention will be described in detail below.

[0031] Nutritional composition

[0032] In a first aspect, the present invention provides a nutritional composition capable of effectively improving vision, such as protecting against blue light damage and / or preventing myopia. The nutritional composition comprises 2'-fucosylated lactose (2'-FL) and 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride (UPU).

[0033] Through research, the inventors have discovered that when 2'-FL is used alone, or when UPU is used alone, it can improve vision, for example, by protecting against blue light damage and / or preventing myopia.

[0034] The inventors have also discovered through research that when 2'-FL and UPU are used in combination, they exhibit a synergistic effect in improving vision, such as protecting against blue light damage and / or preventing myopia. The combined effect is superior to the direct additive effect of the same concentration of 2'-FL alone and the same concentration of UPU alone.

[0035] In embodiments, the mass ratio of 2'-FL to UPU in the nutritional composition can be from 0.01:1 to 20:1, for example, 0.01:1, 0.02:1, 0.03:1, 0.04:1, 0.05:1, 0.052:1, 0.055:1, 0.056:1, 0.058:1, 0.06:1, 0.065:1, 0.07:1, 0.075:1, 0.08:1, 0.083:1, 0.085:1, 0.088:1, 0.09:1, 0.10:1, 0.11:1, 0.12:1, 0.13:1, 0.14:1, 0.15:1, 0.16:1, 0.17:1, 0.18:1, 0.19: 1, 0.20:1, 0.21:1, 0.22:1, 0.23:1, 0.24:1, 0.25:1, 0.26:1, 0.27:1, 0.28:1, 0.29:1, 0.3:1, 0.35:1, 0.38:1, 0.39:1, 0.4:1, 0.42:1, 0.44:1, 0.45:1 0.46:1, 0.48:1, 0.5:1, 0.51:1, 0.52:1, 0.53:1, 0.54:1, 0.55:1, 0.56:1, 0.57:1, 0.58:1, 0.59:1, 0.6:1, 0.61:1, 0.62:1, 0.63:1, 0.64:1, 0.65:1 0.66:1, 0.67:1, 0.68:1, 0.69:1, 0.7:1, 0.71:1, 0.72:1, 0.73:1, 0.74:1, 0.75:1, 0.76:1, 0.77:1, 0.78:1, 0.79:1, 0.8:1, 0.81:1, 0.82:1, 0.83:1 0.84:1, 0.85:1, 0.86:1, 0.87:1, 0.88:1, 0.89:1, 0.9:1, 0.92:1, 0.94:1, 0.95:1, 0.96:1, 0.98:1, 1:1, 1.2:1, 1.4:1, 1.5:1, 1.6:1, 1.8:1, 2:1, 2.2: 1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1, 3:1, 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, 3.9:1, 4:1, 4.2:1, 4.4:1, 4.5:1, 4 6:1, 4.8:1, 5:1, 5.2:1, 5.4:1, 5.5:1, 5.6:1, 5.8:1, 6:1, 6.2:1, 6.4:1, 6.5:1, 6.6:1, 6.8:1, 7:1, 7.2:1, 7.4:1, 7.5:1, 7.6:1, 7.8:1, 8:1, 8.2:1, 8.The ratios of 2'-FL to UPU are 4:1, 8.5:1, 8.6:1, 8.8:1, 9:1, 9.2:1, 9.4:1, 9.5:1, 9.6:1, 9.8:1, 10:1, 10.5:1, 11:1, 11.5:1, 12:1, 12.5:1, 13:1, 13.5:1, 14:1, 14.5:1, 15:1, 15.5:1, 16:1, 16.5:1, 17:1, 17.5:1, 18:1, 18.5:1, 19:1, 19.5:1, 20:1, or within the range defined by any two of these ratios. When the mass ratio of 2'-FL to UPU is within the above ranges, the synergistic effect of the nutritional composition in improving vision, such as protecting against blue light damage and / or preventing myopia, is enhanced.

[0036] In some embodiments, the mass ratio of 2'-FL to UPU in the nutritional composition may be in the range of 0.05:1 to 15:1; within this range, the synergistic effect of the nutritional composition in improving vision, such as protecting against blue light damage and / or preventing myopia, is more significant.

[0037] In some embodiments, the mass ratio of 2'-FL to UPU in the nutritional composition may be in the range of 0.08:1 to 4:1; within this range, the synergistic effect of the nutritional composition in improving vision, such as protecting against blue light damage and / or preventing myopia, is more significant.

[0038] In some embodiments, the mass ratio of 2'-FL to UPU in the nutritional composition may be in the range of 0.22:1 to 3.2:1; within this range, the synergistic effect of the nutritional composition in improving vision, such as protecting against blue light damage and / or preventing myopia, is more significant.

[0039] In some embodiments, the mass ratio of 2'-FL to UPU in the nutritional composition may be in the range of 0.25:1 to 0.8:1; within this range, the synergistic effect of the nutritional composition in improving vision, such as protecting against blue light damage and / or preventing myopia, is more significant.

[0040] In some embodiments, the mass ratio of 2'-FL to UPU in the nutritional composition may be from 0.0833:1 to 12:1, for example, 0.0833:1, 0.25:1, 0.75:1, 1:1, 3:1 or 12:1.

[0041] In implementation, UPU may include one or more, for example, three UPU-type triglycerides.

[0042] For example, the UPU may include one or more of the following: 1,3-dioleoyl-2-palmitoylglycerol triglyceride (OPO), 1-oleoyl-2-palmitoyl-3-linoleic acid triglyceride (OPL), and 1,3-dilinoleoyl-2-palmitoylglycerol triglyceride (LPL).

[0043] Preferably, the UPU comprises a mixture of three UPU-type triglycerides, namely OPO, OPL, and LPL.

[0044] In some embodiments, in the UPU, based on a total triglyceride content of 100%, the OPL mass percentage is 12% to 40% (e.g., 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 22%, 25%, 30%, or 40%), the OPO mass percentage is 5% to 35% (e.g., 5%, 6%, 7%, 8%, 9%, 10%, 15%, 16%, 17%, 18%, 19%, 20%, 22%, 25%, 30%, or 35%), and the LPL mass percentage is... The percentage by weight is 0.3% to 10% (e.g., 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 2.0%, 3.0%, 4.0%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, or 10.0%), and the sum of the masses of OPO, OPL, and LPL is ≥35% (e.g., ≥35%, ≥36%, ≥37%, ≥38%, ≥39%, ≥40%, ≥45%, ≥50%, or higher, more specifically, for example, 50%). For example, in the UPU, with a total triglyceride content of 100%, the sum of the masses of OPO, OPL, and LPL can be in the range of 35% to 100%, for example, 40% to 80%, 40% to 60%, or 40% to 50%.

[0045] In a typical implementation, the UPU may be derived from a mixture of oils rich in OPO, OPL, and LPL. In other words, the UPU may be included in the nutritional composition in the form of a mixture of oils rich in OPO, OPL, and LPL.

[0046] In some embodiments, the oil mixture may include:

[0047] - The following amounts of first triglycerides selected from OPO, OPL, LPL, or mixtures thereof (e.g., a mixture of any two or three of OPO, OPL, and LPL): from about 35% by mass to about 100% by mass, for example, about 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 5 9, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% by mass, or within the range defined by any two of them; and

[0048] - Optionally selected from one or more of OP-Po, OP-Ln, LP-Po, LP-Ln, Eo-PO, DHA-PO, DHA-PL, Di-PO, Da-PL, PPO, LPP, LOO and PPP, wherein the content of PPP is less than 10% by mass.

[0049] In an embodiment, in the first triglyceride, OPO, OPL, and LPL can each independently account for 0-100% by mass of the first triglyceride, for example, approximately 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 5 0, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% by mass, or within the range defined by any two of them, provided that the contents of OPO, OPL, and LPL are not simultaneously 0.

[0050] In embodiments, the oil mixture may consist substantially of triglycerides, for example, of triglycerides. The triglycerides may include, for example, the aforementioned UPU-type triglycerides. In embodiments, 2'-FL may be provided in the form of naturally occurring and / or synthetically derived (e.g., biosynthetic) sources.

[0051] product

[0052] In a second aspect, the present invention provides products comprising a nutritional composition according to the first aspect of the present invention.

[0053] In this implementation, the product may be food or medicine.

[0054] In an implementation, the product, such as a food, may further include one or more selected from plant-based ingredients, animal dairy ingredients, animal meat ingredients, functional additives, and food ingredients.

[0055] The plant-based product ingredients may include, for example, vegetable ingredients, fruit ingredients, grain ingredients, dried fruit ingredients, and medicinal and edible herbal ingredients.

[0056] The animal dairy product ingredients may include, for example, fresh milk from cows, sheep, camels, etc., as well as reprocessed dairy products such as whole milk powder, skim milk powder, whey protein concentrate, desalted whey powder, whey protein powder, and hydrolyzed whey protein powder.

[0057] The animal meat product ingredients may include, for example, meat products from pigs, cattle, sheep, aquatic products, or poultry.

[0058] The functional additives may include, for example, mineral supplements, vitamin supplements, nucleotide supplements, dietary fiber, etc.

[0059] The food additives may include, for example, solvents, antioxidants, thickeners, antibacterial agents, coating materials, etc.

[0060] In this embodiment, the food may include dairy products, health foods, fermented foods, beverages, bread, biscuits, and confectionery.

[0061] In this embodiment, the food product may be infant formula, children's formula, adolescent formula, formula for pregnant women, or formula for the elderly. In this document, infants refer to people aged 0 to 3 years, children to people aged 3 to 6 years, adolescents to people aged 7 to 18 years, and the elderly to people over 40 years of age.

[0062] All descriptions above relating to the first aspect of the present invention are applicable here and will not be repeated here.

[0063] use

[0064] In a third aspect, the present invention provides the use of the nutritional composition according to the first aspect of the invention for the preparation of products for relieving or improving eye strain and / or protecting or improving vision; or the use of the nutritional composition according to the first aspect of the invention for non-therapeutic purposes (nutritional and / or health care) for relieving or improving eye strain and / or protecting or improving vision.

[0065] In implementation, the relief or improvement of eye strain and the protection or improvement of vision may each independently include contributing to protection against blue light damage and / or preventing myopia. Specifically, the relief or improvement of eye strain and the protection or improvement of vision may each independently include both contributing to protection against blue light damage and preventing myopia.

[0066] In an implementation, the anti-blue light damage may include reducing ocular cell apoptosis and / or reducing ocular reactive oxygen species (ROS) accumulation.

[0067] In the implementation, individuals who relieve or improve eye strain and protect or improve vision are not limited to infants and children, but may also include adolescents and the middle-aged and elderly.

[0068] The present invention also provides the use of 2'-FL in the preparation of products (e.g., food or pharmaceuticals) for protection against blue light damage and / or prevention of myopia.

[0069] The present invention also provides the use of compositions comprising a plurality of (e.g., three) UPU-type triglycerides for the preparation of products (e.g., food or pharmaceuticals) for protection against blue light damage and / or prevention of myopia.

[0070] The composition comprising three UPU-type triglycerides may be a mixture of oils and fats described above. A detailed description of the oil and fat mixture is provided above.

[0071] In an embodiment, when the nutritional composition is taken orally in humans, the dosage of 2'-FL can be from 1.6 to 3.6 g / day, for example 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, or 3.6 g / day, or a range defined by any two of them.

[0072] The specific content of UPU in food is not particularly limited, as long as it meets the requirements of relevant food laws and regulations. Preferably, when the nutritional composition is taken orally by humans, the dosage of UPU can be calculated based on the mass ratio of 2'-FL to UPU described herein for the nutritional composition.

[0073] All descriptions above relating to the first and second aspects of the present invention are applicable here and will not be repeated here.

[0074] In the following, the nutritional composition according to the embodiments of the present application will be further described in detail with reference to the examples. However, the following examples are merely exemplary, and the scope of the present application is not limited thereto. In addition, the comparative examples are specifically used to compare with the formulations to highlight the synergistic effect when the components are combined. The comparative examples do not necessarily mean that they are outside the scope of the invention.

[0075] Examples

[0076] Unless otherwise specified, the raw materials used in the present invention can be obtained through commercial channels, and the methods used are all conventional methods in the art.

[0077] 1. Experimental animals

[0078] The zebrafish used in the experiment were all raised in fish culture water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450 to 550 μS / cm; the pH was 6.5 to 8.5; the hardness was 50 to 100 mg / L CaCO3), provided by the fish culture center of Hangzhou Huante Biotechnology Co., Ltd., and the license number for the use of experimental animals was: SYXK(Zhe)2022-0004. The feeding management complied with the requirements of international AAALAC accreditation (accreditation number: 001458), and the IACUC ethical review number was: IACUC-2025-12586-01.

[0079] 2. Sample raw materials

[0080] Coenzyme Q10 (batch number K2211223) and Atropine sulfate monohydrate (atropine, batch number I2111034) were both purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.;

[0081] 2'-Fucosyllactose (2'-FL) was produced by Hongmo Biotechnology (Shanghai) Co., Ltd. (batch number: Z006202412002), and the purity was 99.9%; and

[0082] 1,3-Diunsaturated fatty acid-2-palmitoyl glycerol triglyceride (UPU) was provided by Qingdao Haizhiyuan Life Science and Technology Co., Ltd. This raw material is an oil mixture and is characterized in that the sum of the masses of OPO, OPL and LPL accounts for 45.97% of the total triglyceride mass, and the mass of PPP accounts for less than 10% of the total triglyceride mass.

[0083] In the examples, unless otherwise specifically stated, the dosage ratio of 2'-FL / UPU refers to the mass ratio of 2'-FL relative to UPU. The mass of UPU is calculated based on the sum of the masses of OPO, OPL and LPL.

[0084] 3. Instruments, consumables, and reagents:

[0085] Dissecting microscope (SZX7, OLYMPUS, Japan);

[0086] CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China);

[0087] Precision electronic balance (CP214, OHAUS, USA);

[0088] 6-well plate (Zhejiang Beilanbo Biotechnology Co., Ltd., China);

[0089] Blue light transilluminator (50W 450nm, China);

[0090] Motorized focusing continuous zoom fluorescence microscope (AZ100, Nikon, Japan);

[0091] Ultrasonic cleaning machine (JP-010T, Shenzhen Jiemeng Cleaning Equipment Co., Ltd., China);

[0092] Multifunctional microplate reader (SPARK, TECAN, Austria);

[0093] 96-well microplate (Costar, China);

[0094] Microinjection apparatus (IM300, Narishige, Japan);

[0095] Needle puller (PC-10, Narishige, Japan);

[0096] Precision electronic balance (CP214, OHAUS, USA);

[0097] Methylcellulose (batch number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China);

[0098] Dimethyl sulfoxide (DMSO, batch number I2229063, Shanghai Aladdin Biochemical Technology Co., Ltd., China);

[0099] Acridine Orange (AO, batch number C15109250, Shanghai Maclean Biochemical Technology Co., Ltd., China);

[0100] Streptase E (batch number G12511Y118034, Shanghai Yuanye Biotechnology Co., Ltd., China); and

[0101] CM-H2DCFDA (lot number 2505981, Invitrogen, USA).

[0102] Evaluation Experiment 1: Evaluation of Anti-Blue Light Damage Efficacy

[0103] The experimental groups involved in the following experiments include:

[0104] Normal control group: No blue light exposure and no intervention treatment;

[0105] Model control group: Irradiated with blue light, but without intervention;

[0106] Positive control group: Irradiated with blue light and treated with an intervention, namely coenzyme Q10;

[0107] Single samples (2'-FL, UPU, or comparative examples 1 to 6): irradiated with blue light and treated with an intervention, said intervention being the corresponding single sample; and

[0108] Compositions (Formulas 1 to 6): Irradiated with blue light and treated with an intervention, said intervention being the corresponding composition.

[0109] 1. Determination of the maximum tolerated concentration (MTC) for a single sample

[0110] Wild-type AB strain zebrafish were randomly selected one day after fertilization (1 dpf) and exposed to blue light immediately after rupture to establish a zebrafish blue light-induced eye damage model. At 3 dpf, well-developed model zebrafish were randomly assigned to 6-well plates, with 30 zebrafish treated in each well (experimental group). Samples were administered in water (concentrations shown in Table 1), and a normal control group and a model control group were also included. The volume of each well was 3 mL. After treatment at 28℃ for one day, the MTC of the samples in the model zebrafish was measured.

[0111] Table 1. Results of MTC exploration in the experiment on the resistance of samples to blue light damage

[0112]

[0113] The experimental results shown in Table 1 indicate that the MTC for detecting the anti-blue light damage efficacy of 2'-FL and UPU is 2000 μg / mL. Subsequent experimental designs will be conducted with reference to the above MTC.

[0114] 2. Evaluation experiment on the efficacy of the sample in resisting blue light damage

[0115] 2.1 Evaluation Experiment of the Sample's Efficacy in Inhibiting Ocular Cell Apoptosis

[0116] Wild-type AB strain zebrafish at 1 dpf were randomly selected and exposed to blue light after rupture to establish a zebrafish blue light eye damage model. At 3 dpf, well-developed model zebrafish were randomly assigned to 6-well plates, with 30 zebrafish treated in each well (experimental group). Samples were administered in water (concentrations shown in Table 2). The positive control group was treated with 62.5 μg / mL coenzyme Q10. Normal and model control groups were also included, with a volume of 3 mL per well. After treatment at 28℃ for one day, zebrafish in each experimental group underwent AO staining in the dark for 30 minutes. After washing three times with standard dilution water, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. ImageJ software was used to analyze and collect data, and the fluorescence intensity of apoptotic cells in the zebrafish eyes was analyzed and statistically analyzed. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance.

[0117] Table 2. Evaluation Results of Anti-Blue Light Damage Efficacy (Inhibition of Ocular Cell Apoptosis)

[0118]

[0119]

[0120] Note:

[0121] (1) The concentrations shown in the table are for pure products;

[0122] (2) The meanings of the symbols related to the p-value are as follows:

[0123] Compared with the model control group, *p < 0.05, **p < 0.01, ***p < 0.001;

[0124] Compared with Comparative Example 1, # p < 0.05;

[0125] Compared with Comparative Example 2, ^p < 0.05;

[0126] Compared with Comparative Example 3, $$ p < 0.01;

[0127] Compared with Comparative Example 4, %% p < 0.01, %%% p < 0.001;

[0128] Compared with Comparative Example 5, & p < 0.05.

[0129] From Table 2, Figure 1 and Figure 2It was found that after blue light irradiation, the fluorescence intensity of apoptotic cells in the eyes of the model control group was significantly higher than that of the normal control group (p < 0.001), indicating that blue light irradiation significantly increased apoptosis of zebrafish eye cells, i.e., blue light irradiation modeling caused zebrafish eye damage. Furthermore, compared with the model control group, the fluorescence intensity of apoptotic cells in the eyes of the positive control group was significantly lower. Therefore, the modeling was successful.

[0130] Compared with the model control group, the fluorescence intensity of apoptotic cells in the eyes of zebrafish treated with 2'-FL (250 μg / mL, 1000 μg / mL) or UPU (750 μg / mL) alone was significantly reduced (p < 0.05), suggesting that the single sample has anti-blue light effect, specifically by inhibiting apoptosis of eye cells.

[0131] Furthermore, compared with the model control group, the combination of 2'-FL and UPU (formulas 1 to 6) significantly reduced the degree of ocular cell apoptosis in zebrafish (p < 0.05), indicating that the composition containing 2'-FL and UPU has the effect of resisting blue light damage, specifically by inhibiting ocular cell apoptosis.

[0132] Furthermore, compared with the model control group, the combination of 2'-FL and UPU (formulas 1 to 6) exhibited a synergistic effect in combating blue light damage, particularly in inhibiting ocular cell apoptosis. This synergistic effect can be characterized by a synergistic coefficient. Considering the dosage of the components, the strength of the synergistic effect can be further characterized by the synergistic coefficient per unit dose (also known as the contribution rate of the unit dose to the synergistic coefficient).

[0133] The synergistic coefficient of the formulation can be calculated according to Equation 1, and the synergistic coefficient per unit dose of the formulation can be calculated according to Equation 2:

[0134] Equation 1

[0135] Synergy coefficient = (reduction in ocular apoptotic cell fluorescence intensity of the formulation compared to the model control group) / (sum of reduction in ocular apoptotic cell fluorescence intensity of the two corresponding samples in the formulation compared to the model control group);

[0136] Equation 2

[0137] Synergy coefficient per unit dose = synergy coefficient of the formulation / sum of the doses of the two components of the formulation.

[0138] The synergy coefficient is the ratio of the improvement brought about by the combination of 2'-FL and UPU to the sum of the improvements brought about by the corresponding two individual samples (comparative examples). A synergy coefficient greater than 1 indicates a synergistic effect. The larger the synergy coefficient, the better the effect.

[0139] The synergistic coefficient per unit dose reflects the strength of the synergistic effect of formulations containing different doses of 2'-FL and UPU. The larger the synergistic coefficient per unit dose, the stronger the contribution of the unit dose to the synergistic effect.

[0140] Since each well has the same volume, the dose is directly proportional to the concentration. For the sake of simplicity, only the concentration is used, without further introducing the well volume, to calculate the synergistic coefficient per unit dose.

[0141] Taking Formulation 1 as an example, Formulation 1 (2'-FL+UPU) is equivalent to a combination of Comparative Example 1 (2'-FL) and Comparative Example 4 (UPU). Formulation 1, Comparative Example 1, and Comparative Example 4 reduced the fluorescence intensity of apoptotic cells in zebrafish eyes by 11290 pixels, 4885 pixels, and 5263 pixels, respectively. The synergy coefficient of Formulation 1 = 11290 / (4885+5263) = 1.11. That is, the decrease in fluorescence intensity of apoptotic cells in the eyes by Formulation 1 (11290) is greater than the sum of the decreases by Comparative Example 1 and Comparative Example 4 (10148). Furthermore, considering the concentrations of each component (2'-FL: 62.5 μg / mL, UPU: 83.3 μg / mL), the synergy coefficient per unit dose of Formulation 1 = 1.11 / (62.5+83.3) = 0.0076.

[0142] As shown in Table 2, the synergistic coefficients of formulations 1 to 6 are all greater than 1, which indicates that 2'-FL and UPU have a synergistic effect in resisting blue light damage, especially in inhibiting ocular cell apoptosis.

[0143] In formulations 1 to 6, the mass ratio of 2'-FL to UPU is 0.0833 to 12. Therefore, formulations with a mass ratio of 2'-FL to UPU of 0.0833 to 12 have a synergistic effect in protecting against blue light damage, especially in inhibiting ocular cell apoptosis.

[0144] Furthermore, as shown in Table 2, formulations 1 through 6 all exhibit satisfactory synergistic coefficients per unit dose.

[0145] Specifically, the synergistic coefficients per unit dose of formulations 1, 2, 4, 5, 3, and 6, in which the mass ratios of 2'-FL to UPU are 0.75, 0.25, 3, 1, 0.0833, and 12, decrease sequentially. Therefore, satisfactory synergistic coefficients per unit dose can be obtained when the mass ratio of 2'-FL to UPU is in the range of 0.0833 to 12, preferably 0.0833 to 3, more preferably 0.25 to 3, and even more preferably 0.25 to 0.75.

[0146] In particular, compared with other formulations, formulations 1 and 2, in which the mass ratio of 2'-FL to UPU is 0.75 and 0.25, respectively, simultaneously achieved relatively high synergistic coefficients and relatively high synergistic coefficients per unit dose. Therefore, the mass ratio of 2'-FL to UPU in the range of 0.25 to 0.75 is particularly outstanding in its synergistic effect against blue light damage, especially in inhibiting ocular cell apoptosis.

[0147] To investigate whether the combination of 2'-FL and UPU could inhibit ocular apoptosis beyond the effect achievable at the maximum tolerated concentration of either ingredient, the inventors also tested the effects of the maximum tolerated concentration of 2'-FL or UPU on inhibiting ocular apoptotic cells (Table 3). To measure the degree of improvement, the inventors calculated the improvement ratio using Equation 3 and present it in Table 3.

[0148] Equation 3

[0149] Improvement rate = (sample mean - model control group mean) / (normal control group mean - model control group mean).

[0150] Table 3. Evaluation results of the samples' anti-blue light efficacy (inhibition of ocular cell apoptosis) (n = 10)

[0151]

[0152] Compared with the model control group, **p < 0.01, ***p < 0.001.

[0153] As shown in Table 3, the improvement rate of ocular cell apoptosis in zebrafish with blue light damage was 44.05% when 2'-FL was used alone at 2000 μg / mL, and the improvement rate of ocular cell apoptosis in zebrafish with blue light damage was 39.73% when UPU was used alone at 2000 μg / mL.

[0154] Similarly, the improvement rates of formulations 1 to 6 were calculated according to Equation 3. The results showed that the improvement rates of apoptosis of ocular cells in zebrafish caused by blue light damage by formulations 1, 2, 3, 4, 5, and 6 were 26.09%, 33.82%, 43.42%, 35.96%, 40.79%, and 57.67%, respectively.

[0155] The results above show that although the concentrations of UPU used in formulations 3, 5, and 6 were much lower than the maximum tolerated concentration, the improvement in blue light-damaged apoptotic cells in zebrafish eyes exceeded the effect achievable with the maximum tolerated concentration of UPU alone. Similarly, although the concentration of 2'-FL used in formulation 6 was much lower than the maximum tolerated concentration, the improvement in blue light-damaged apoptotic cells in zebrafish eyes also exceeded the effect achievable with the maximum tolerated concentration of 2'-FL alone. Furthermore, although the concentrations of both 2'-FL and UPU used in formulations 1, 2, and 4 were all much lower than the maximum tolerated concentration, they still achieved high improvement rates ranging from 26.09% to 35.96%.

[0156] 2.2 Ocular ROS Evaluation Experiment for Sample Removal

[0157] Wild-type AB strain zebrafish at 1 dpf were randomly selected and exposed to blue light after rupture to establish a zebrafish blue light eye damage model. At 3 dpf, well-developed model zebrafish were randomly assigned to 6-well plates, with 30 zebrafish treated in each well (experimental group). Samples were administered in water (concentrations shown in Table 4), and a positive control group was treated with 62.5 μg / mL coenzyme Q10. A normal control group and a model control group were also included, with a volume of 3 mL per well. After treatment at 28℃ for 1 day, the zebrafish were transferred to 6-well plates and diluted with ROS fluorescence detection solution to 2 mL per well. Subsequently, the zebrafish from each experimental group were transferred to black 96-well microplates, 3 zebrafish / well, with a volume of 150 µL per well. ROS fluorescence values ​​of the zebrafish in each experimental group were analyzed using a multi-functional microplate reader. The statistical analysis results of this index were used to evaluate the anti-blue light efficacy (ROS scavenging efficacy) of the samples. Statistical results are expressed as mean ± SE. Statistical analysis using SPSS software showed that p < 0.05 was statistically significant.

[0158] Table 4. Evaluation Results of Anti-Blue Light Efficacy (ROS Removal Efficacy)

[0159]

[0160] Note:

[0161] (1) The concentrations shown in the table are for pure products;

[0162] (2) Compared with the model control group, *p < 0.05, **p < 0.01, ***p < 0.001;

[0163] Compared with Comparative Example 1, # p < 0.05, ## p < 0.01;

[0164] Compared with Comparative Example 2, ^p < 0.05;

[0165] Compared with Comparative Example 4, % p < 0.05, %%% p < 0.001

[0166] Compared with Comparative Example 5, & p < 0.05.

[0167] From Table 4 and Figure 3 It was found that after blue light irradiation, the ROS fluorescence value in the model control group was significantly higher than that in the normal control group (p < 0.001), indicating that blue light irradiation caused abnormal ROS accumulation in zebrafish, i.e., blue light irradiation modeling caused eye damage in zebrafish. Furthermore, compared with the model control group, the ROS fluorescence value in the positive control group was significantly decreased. Therefore, the modeling was successful.

[0168] Compared with the model control group, the ROS fluorescence values ​​of the groups treated with 2'-FL (250 μg / mL, 1000 μg / mL) or UPU (250 μg / mL, 750 μg / mL) alone were significantly reduced (P<0.05), indicating that the single sample has anti-blue light effect, specifically by increasing the scavenging of ROS.

[0169] Furthermore, compared with the model control group, the combination of 2'-FL and UPU (formulas 1 to 6) significantly improved the scavenging effect on ROS (p < 0.05), indicating that the composition containing 2'-FL and UPU has the effect of resisting blue light damage, specifically by clearing more ocular ROS.

[0170] In addition, compared with the model control group, the combination of 2'-FL and UPU (formulas 1 to 6) has a synergistic effect in resisting blue light damage, especially in clearing ocular ROS.

[0171] Similar to the efficacy evaluation experiment for inhibiting ocular cell apoptosis, the synergistic coefficient of the formulation can be calculated according to Equation 4.

[0172] Equation 4

[0173] Synergy coefficient = Reduction in ROS fluorescence value of the formulation compared to the model control group / Sum of the reduction in ROS fluorescence value of the two corresponding samples in the formulation compared to the model control group.

[0174] In addition, the synergistic coefficient of the formulation per unit dose can be calculated according to Equation 2 in Evaluation Experiment 1.

[0175] Taking Formulation 1 as an example, Formulation 1 is equivalent to a combination of Comparative Example 1 and Comparative Example 4. Formulation 1, Comparative Example 1, and Comparative Example 4 reduced the ROS fluorescence value of zebrafish by 331, 102, and 185, respectively. The synergy coefficient of Formulation 1 = 331 / (102+185) = 1.15. That is, the reduction in ROS fluorescence value of Formulation 1 (331) is greater than the sum of the reductions of Comparative Example 1 and Comparative Example 4 (287). Furthermore, considering the concentrations of each component (2'-FL: 62.5 μg / mL, UPU: 83.3 μg / mL), the synergy coefficient per unit dose of Formulation 1 = 1.15 / (62.5+83.3) = 0.0079.

[0176] As shown in Table 4, the synergy coefficients of formulations 1 to 6 are all greater than 1, which indicates that 2'-FL and UPU have a synergistic effect in resisting blue light damage, especially in clearing ocular ROS.

[0177] In formulations 1 to 6, the mass ratio of 2'-FL to UPU is 0.0833 to 12. Therefore, formulations with a mass ratio of 2'-FL to UPU of 0.0833 to 12 have a synergistic effect in resisting blue light damage, especially in scavenging ROS.

[0178] Furthermore, as shown in Table 4, formulations 1 through 6 all exhibit satisfactory synergistic coefficients per unit dose.

[0179] Specifically, the synergistic coefficients per unit dose of formulations 1, 2, 4, 5, 3, and 6, in which the mass ratios of 2'-FL to UPU are 0.75, 0.25, 3, 1, 0.0833, and 12, decrease sequentially. Therefore, satisfactory synergistic coefficients per unit dose can be obtained when the mass ratio of 2'-FL to UPU is in the range of 0.0833 to 12, preferably 0.0833 to 3, more preferably 0.25 to 3, and even more preferably 0.25 to 0.75.

[0180] In particular, compared with other formulations, formulations 1 and 2, in which the mass ratio of 2'-FL to UPU is 0.75 and 0.25 respectively, simultaneously achieved relatively high synergistic coefficients and relatively high synergistic coefficients per unit dose. Therefore, the mass ratio of 2'-FL to UPU in the range of 0.25 to 0.75 is particularly outstanding in its synergistic effect on anti-blue light damage, especially in scavenging ROS.

[0181] Evaluation Experiment 2: Evaluation of the efficacy in preventing myopia

[0182] 1. Determination of the maximum tolerated concentration (MTC) for a single sample

[0183] Studies have shown that injecting zebrafish with lumican-MO (an antisense oligonucleotide used to knock down the expression of the lumican gene in zebrafish) can cause excessive expansion of the sclera in zebrafish, leading to myopia, which is consistent with the characteristics of high myopia in humans.

[0184] Wild-type AB strain zebrafish at the single-cell stage were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well. Except for the normal control group, all other groups were injected with lumican-MO to establish a zebrafish myopia model. After treatment at 28 ℃ for 2 days, the samples were administered in water solution (concentrations shown in Table 5). A normal control group and a model control group were also included, with a volume of 3 mL per well. After further treatment at 28 ℃ for 3 days, the MTC of the samples in the model zebrafish was measured.

[0185] Table 5. Results of the experiment to determine the maximum detection concentration of the sample's efficacy in preventing myopia.

[0186]

[0187] The experimental results in Table 5 show that the median concentration (MTC) for detecting the myopia prevention efficacy of 2'-FL was 2000 μg / mL, and the MTC for detecting the myopia prevention efficacy of UPU was 1000 μg / mL. Subsequent dosing experiments were designed with reference to the above MTC values.

[0188] 2. Experiment evaluating the efficacy of samples in preventing myopia

[0189] Wild-type AB strain zebrafish at the single-cell stage were randomly selected and placed in 6-well plates, with 30 zebrafish per well. A portion of the zebrafish were left untreated and used as the normal control group. Another portion of zebrafish were injected with 2 nL (nanoliters) / zebrafish lumican-MO (an antisense oligonucleotide used to knock down the expression of the lumican gene in zebrafish) to impair vision, thus establishing a zebrafish myopia model for setting up a model control group, positive control group, and experimental group. Another portion of zebrafish underwent the same experimental procedure as the model control group, receiving a single injection of 2 nL (nanoliters) / zebrafish standard MO (an antisense oligonucleotide that does not affect the expression of any zebrafish gene), serving as the MO standard control group. After treatment at 28℃ for 2 days, except for the normal control group, MO standard control group, and model control group, the experimental group and positive control group were treated with water-soluble samples (concentrations shown in Table 6) or the positive control Atropine sulfate monohydrate (2500 μg / mL concentration), with a volume of 3 mL per well. After further treatment at 28℃ for 3 days, 10 zebrafish were randomly selected from each experimental group, photographed under a dissecting microscope, and the images were saved. Data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The ratio of retinal pigment epithelium diameter to scleral diameter was analyzed, and the statistical analysis results of this index were used to evaluate the myopia prevention efficacy of the samples. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated a statistically significant difference.

[0190] Table 6. Experimental Results of Myopia Prevention Efficacy Evaluation

[0191]

[0192]

[0193] Note:

[0194] (1) The concentrations shown in the table are for pure products;

[0195] (2) Compared with the model control group, *p < 0.05, **p < 0.01, ***p < 0.001;

[0196] Compared with Comparative Example 1, # p < 0.05, ## p < 0.01, ### p < 0.001;

[0197] Compared with Comparative Example 2, ^^p < 0.01;

[0198] Compared with Comparative Example 4, %%%p < 0.001;

[0199] Compared with Comparative Example 5, && p < 0.01.

[0200] From Table 6, Figure 4 and Figure 5 It was found that after injecting lumican-MO into zebrafish, the ratio of retinal pigment epithelium diameter to scleral diameter in the model control group was significantly reduced compared to the normal control group (p < 0.001), indicating successful myopia modeling. Furthermore, compared to the model control group, the ratio of retinal pigment epithelium diameter to scleral diameter in the positive control group was significantly increased. Therefore, myopia modeling was successful.

[0201] Compared with the model control group, the groups treated with 2'-FL (250 μg / mL, 1000 μg / mL) and UPU (250 μg / mL, 750 μg / mL) alone had a significantly increased ratio of retinal pigment epithelium diameter to scleral diameter (p < 0.05), suggesting that each sample has a preventive effect against myopia.

[0202] Furthermore, compared with the model control group, the combination of 2'-FL and UPU (formulas 1 to 6) significantly increased the retinal pigment epithelium diameter / scleral diameter (p < 0.05), suggesting that the formulation has a myopia prevention effect.

[0203] Similar to the evaluation experiment 1, the synergistic coefficient of the formulation can be calculated according to Equation 5.

[0204] Equation 5

[0205] Synergy coefficient = (the ratio of the increase in retinal pigment epithelium diameter to scleral diameter of the formulation compared to the model control group) / (the sum of the ratios of the increase in retinal pigment epithelium diameter to scleral diameter of the two corresponding samples in the formulation compared to the model control group).

[0206] In addition, the synergistic coefficient of the formulation per unit dose can be calculated according to Equation 2 in Evaluation Experiment 1.

[0207] Taking Formula 1 as an example, Formula 1 is equivalent to a combination of Comparative Example 1 and Comparative Example 4. The ratios of increased retinal pigment epithelium diameter / scleral diameter compared to the model control group for Formula 1, Comparative Example 1, and Comparative Example 4 are 0.037, -0.002, and 0.011, respectively. The synergistic coefficient of Formula 1 = 0.037 / (-0.002+0.011) = 4.11. That is, the increased retinal pigment epithelium diameter / scleral diameter ratio of Formula 1 (0.037) is greater than the sum of the increases of Comparative Example 1 and Comparative Example 4 (0.009). Furthermore, considering the concentrations of each component (2'-FL: 62.5 μg / mL, UPU: 83.3 μg / mL), the synergistic coefficient per unit dose of Formula 1 = 4.11 / (62.5+83.3) = 0.0282.

[0208] As shown in Table 6, the synergy coefficients of formulations 1 to 6 are all greater than 1, indicating that 2'-FL and UPU have a synergistic effect in preventing myopia.

[0209] In formulations 1 to 6, the mass ratio of 2'-FL to UPU is 0.0833 to 12. Therefore, formulations in which the mass ratio of 2'-FL to UPU is 0.0833 to 12 have a synergistic effect in preventing myopia.

[0210] Furthermore, as shown in Table 6, formulations 1 through 6 all exhibit satisfactory synergistic coefficients per unit dose.

[0211] Specifically, the synergistic coefficients per unit dose of formulations 1, 2, 4, 5, 3, and 6, in which the mass ratios of 2'-FL to UPU are 0.75, 0.25, 3, 1, 0.0833, and 12, decrease sequentially. Therefore, satisfactory synergistic coefficients per unit dose can be obtained when the mass ratio of 2'-FL to UPU is in the range of 0.0833 to 12, preferably 0.0833 to 3, more preferably 0.25 to 3, and even more preferably 0.25 to 0.75.

[0212] To investigate whether the combination of 2'-FL and UPU in preventing myopia could exceed the effect achievable at the maximum tolerated concentration of either substance, the inventors also tested the effects of the maximum tolerated concentration of 2'-FL or UPU in preventing myopia (Table 7). To measure the degree of improvement, the inventors calculated the improvement ratio using Equation 3 in Evaluation Experiment 1, and the results are shown in Table 7.

[0213] Table 7. Experimental results evaluating the efficacy of the samples in preventing myopia (n = 10)

[0214]

[0215] As shown in Table 7, the improvement rate of myopia in myopic zebrafish by using 2'-FL alone at 2000 μg / mL was 58.92%, and the improvement rate of ocular cell apoptosis in blue light-damaged zebrafish by using UPU alone at 1000 μg / mL was 53.51%.

[0216] Similarly, the improvement rates of formulas 1 to 6 were calculated according to Equation 3. The results showed that the improvement rates of myopia in myopic zebrafish by formulas 1, 2, 3, 4, 5, and 6 were 21.14%, 30.29%, 53.71%, 45.14%, 58.29%, and 68.57%, respectively.

[0217] The results above show that although the concentrations of UPU used in formulas 3, 5, and 6 are much lower than the maximum tolerated concentration, the improvement rate of myopia achieved by these formulas exceeds the effect achievable by the maximum tolerated concentration of UPU alone. Similarly, although the concentration of 2'-FL used in formula 6 is much lower than the maximum tolerated concentration, the improvement rate of myopia achieved by formula 6 exceeds the effect achievable by the maximum tolerated concentration of 2'-FL alone. Furthermore, although the concentrations of both 2'-FL and UPU used in formulas 1, 2, and 4 are all much lower than the maximum tolerated concentration, they still achieved improvement rates of 21.14% to 45.14% in myopia.

[0218] In this invention, by using the combination of 2'-FL and UPU, the effects of improving vision, specifically resisting blue light damage (specifically, inhibiting ocular cell apoptosis and clearing ocular ROS) and preventing myopia are achieved.

[0219] It should be understood that the above descriptions are merely exemplary embodiments of this application. It should be understood that the descriptions of features or aspects in each exemplary embodiment should typically be considered applicable to other similar features or aspects in other exemplary embodiments, unless there is an obvious contradiction. Those skilled in the art will understand that various changes in form and detail may be made therein without departing from the spirit and scope defined by the appended claims.

Claims

1. A nutritional composition, characterized in that, The nutritional composition comprises 2'-fucosyllactose and 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride, and in the nutritional composition, the mass ratio of 2'-fucosyllactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.4:1 to 0.9:1 or 2:1 to 8:

1.

2. The nutritional composition according to claim 1, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.65:1 to 0.85:1 or 2.5:1 to 6:

1.

3. The nutritional composition according to claim 1, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.7:1 to 0.8:1 or 3:1 to 5:

1.

4. The nutritional composition according to claim 1, characterized in that, The 1,3-diunsaturated fatty acid-2-palmitoyl triglyceride includes one or more of the following: 1,3-dioleoyl-2-palmitoyl triglyceride, 1-oleic-2-palmitoyl-3-linoleic acid triglyceride, and 1,3-dilinoleoyl-2-palmitoyl triglyceride.

5. The nutritional composition according to claim 4, characterized in that, Based on a total triglyceride content of 100%, the sum of the masses of 1,3-dioleoyl-2-palmitoyl triglyceride, 1-oleoyl-2-palmitoyl-3-linoleic acid triglyceride, and 1,3-dilinoleoyl-2-palmitoyl triglyceride is greater than or equal to 35%.

6. A product comprising the nutritional composition according to any one of claims 1 to 5.

7. The product according to claim 6, characterized in that, The product in question is a food product.

8. The product according to claim 7, characterized in that, The food products include dairy products, health foods, fermented foods, beverages, bread, biscuits, and confectionery.

9. The product according to claim 7, characterized in that, The food products mentioned are infant formula, children's formula, youth formula, formula for pregnant women, or formula for the middle-aged and elderly.

10. The use of a nutritional composition in the preparation of a product for improving eyesight, characterized in that, The nutritional composition includes 2'-fucosylated lactose and 1,3-diunsaturated fatty acid-2-palmitoylglycerol.

11. The use according to claim 10, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.05:1 to 15:

1.

12. The use according to claim 10, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.08:1 to 4:

1.

13. The use according to claim 10, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.22:1 to 3.2:

1.

14. The use according to claim 10, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.25:1 to 0.8:

1.

15. The use according to claim 10, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.4:1 to 0.9:1 or 2:1 to 8:

1.

16. The use according to claim 10, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.65:1 to 0.85:1 or 2.5:1 to 6:

1.

17. The use according to claim 10, characterized in that, In the nutritional composition, the mass ratio of 2'-fucosylated lactose to 1,3-diunsaturated fatty acid-2-palmitoylglycerol triglyceride is in the range of 0.7:1 to 0.8:1 or 3:1 to 5:

1.

18. The use according to claim 10, characterized in that, The 1,3-diunsaturated fatty acid-2-palmitoyl triglyceride includes one or more of the following: 1,3-dioleoyl-2-palmitoyl triglyceride, 1-oleic-2-palmitoyl-3-linoleic acid triglyceride, and 1,3-dilinoleoyl-2-palmitoyl triglyceride.

19. The use according to claim 10, characterized in that, Based on a total triglyceride content of 100%, the sum of the masses of 1,3-dioleoyl-2-palmitoyl triglyceride, 1-oleoyl-2-palmitoyl-3-linoleic acid triglyceride, and 1,3-dilinoleoyl-2-palmitoyl triglyceride is greater than or equal to 35%.

20. The use according to claim 10, characterized in that, The improvement in vision includes protection against blue light damage and / or prevention of myopia.

21. The use according to claim 10, characterized in that, The product in question is a food product.

Images